Stock Market

2024’s Worst S&P 500 Stocks So Far From Boeing To Intel


Topline

Several notable companies glumly watched the historic stock market run to open 2024 from the sidelines, with returns on investments looking relatively grim for a neighborhood staple, the world’s most valuable yoga pant hawker, the oldest name in semiconductor chips and the U.S.’ largest plane manufacturer.

Key Facts

The drug store chain Walgreens was the worst-performing company on the S&P 500, the benchmark which tracks the share prices of 500 of the largest U.S.-listed public companies, over the first six months of the year, as Walgreens’ share price halved and hit their lowest level since the mid-1990s, a dive coinciding with the company’s plans to shut up to a quarter of its locations as analysts forecast Walgreens’ worst annual profit since 2013.

Lululemon, the high-end athletic wear firm, is the second-worst-performing stock year-to-date on the S&P, as analysts expect the retailer to post its worst annual revenue growth since Lululemon went public in 2007, other than the fiscal year ending Jan. 2021 weighed down by the COVID-19 pandemic.

Intel, the third-worst performer on the S&P, is perhaps the most surprising loser considering rival Nvidia and other silicon chip companies are among the best-returning investments this year during the AI fever, with Intel shares largely a victim of an extended decline in the company’s business as competition swelled, with some analysts going so far as to declare Intel a “broken company.”

Intel’s $1.8 billion first-quarter earnings before interest, taxes, depreciation and amortization mark its second-worst Q1 figure dating back to at least 2000, an improvement from last year’s $962 million EBITDA but an 82% decline from Q1 2020’s $10.3 billion; for reference, Nvidia’s spring quarter net earnings grew from $1.1 billion to $17.3 billion from 2020 to 2024.

Boeing, the S&P’s 10th-lowest returner, is certainly not a shocking faller: Its stock market woes came as the aerospace firm grappled with a big public relations nightmare after several of its commercial aircrafts malfunctioned, launching a Justice Department probe, a congressional hearing focused on its struggles and its worst quarterly revenues in eight quarters this spring, all frustrating investors with Boeing on a five-year streak of negative profits.

It’s been far from a picture-perfect 2024 for shares of entertainment giants Warner Bros. Discovery and Paramount Global, the fifth- and 12th-biggest losers on the S&P, respectively, as both HBO parent WBD and CBS parent Paramount contended with shaky balance sheets— WBD and Paramount reported $966 million and $563 million respective net losses during Q1—far worse than Wall Street’s Hollywood favorite Netflix’s $2.2 billion net income.

Negative headlines similar drove down the entertainment conglomerates, and WBD’s expected loss of NBA rights caused a 10% single-day selloff April 30, while Paramount’s stock plunged 8% on June 11 after it ended talks of a sale to Skydance Media, which is run by centibillionaire Larry Ellison’s son David Ellison.

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

Worst-Performing Stocks This Year

  1. Walgreens, down 52%
  2. Lululemon, down 42%
  3. Intel, down 38%
  4. EPAM Systems, down 37%
  5. Warner Bros. Discovery, down 35%
  6. Albemarle, down 33%
  7. Globe Life, down 32%
  8. MarketAxess, down 31%
  9. Paycom, down 31%
  10. Boeing, down 30%

Big Number

$170 billion. That’s about how much market value Tesla lost in the first half, by far the most of any S&P company. Shares of the Elon Musk-led electric vehicle maker fell more than 20% as the company reported its third consecutive quarter of negative earnings growth, with consensus analyst data predicting another 35% year-over-year decline in 2024’s second quarter.

Surprising Fact

The worst-performing stock on the Russell 3000, which casts a wider net than the S&P and covers 3,000 of the largest U.S.-listed companies, is drugmaker Aerovate Therapeutics, whose market cap went from over $600 million to below $50 million this year due to a “worst-case scenario” in which its only product, a blood pressure treatment, was pulled from testing. The Russell 3000’s worst performers with market values over $10 billion are fellow electric vehicle maker Rivian, which reported its 11th consecutive quarter of more than $1 billion worth of cash burning.

Contra

Less than 40% of S&P constituent stocks declined during 2024’s first half as the index shot up to an all-time high.



Source link

Leave a Response